Recent Comments

Comment RSS

Osteoarthritis News and Research RSS Feed - Osteoarthritis News and Research

According to the Arthritis Foundation, 66 million (nearly one in three adults) suffer from chronic joint pain and 21 million Americans suffer from osteoarthritis (OA), the most common form of arthritis, which is characterized by a breakdown of the cartilage and a deterioration of the fluid in a joint. The symptoms of osteoarthritis include pain, from moderate to severe, and stiffness. Most people who have osteoarthritis are older than age 45, and women are more commonly affected than men.

World Congress on Osteoporosis 2010: Researchers invited to contribute their abstracts

21. November 2009 03:46
Researchers are invited to contribute their abstracts to the World Congress on Osteoporosis 2010 (IOF WCO - ECCEO10), the largest global meeting devoted to all aspects of osteoporosis and osteoarthritis research and patient care. The Congress will be held in Florence, Italy from May 5-8, 2010. [More]

Posted in: Medical Condition News

Tags: , , , , ,

Canadian Arthritis Network to host 2009 Annual Scientific Conference in Vancouver

19. November 2009 22:37
People with arthritis and leading Canadian and international researchers will share the stage under the theme "Decoding Arthritis - A Joint Effort" when the Canadian Arthritis Network (CAN) hosts its 2009 Annual Scientific Conference beginning tonight, in Vancouver, BC. [More]

Posted in: Medical Condition News

Tags: , , , ,

Anika Therapeutics' "ELEVESS Light" receives European CE Mark approval

19. November 2009 09:27
Anika Therapeutics, Inc., a leader in products for tissue protection, healing and repair based on hyaluronic acid (“HA”) technology, today announced that it has received European CE Mark approval for “ELEVESS™ Light,” the Company’s latest aesthetic product used for the treatment of fine lines and facial wrinkles. ELEVESS Light will be distributed in the European market by the Company’s current aesthetic dermatology distributors. [More]

Posted in: Device / Technology News

Tags: , ,

OA panel develops a consensus of the optimal exogenous HA treatment using BioRestorative Profiling

19. November 2009 06:30
A panel of osteoarthritis (OA) key opinion leaders has developed a consensus of the optimal exogenous hyaluronic acid (HA) treatment. This consensus was achieved by utilizing what the experts referred to as BioRestorative(TM) Profiling. This profiling examines HAs on the basis of their mimicking the body's natural HA. [More]

Posted in: Device / Technology News | Medical Condition News

Tags: , , , ,

New Drug Application for NicOx's naproxcinod accepted for filing

18. November 2009 04:01
NicOx S.A. today announced that it has received a filing communication from the U.S. Food and Drug Administration (FDA) stating that the New Drug Application (NDA) for naproxcinod is accepted for filing. NicOx submitted the NDA on September 24th, seeking approval for the relief of the signs and symptoms of osteoarthritis. [More]

IntelGenx completes first successful human study of an anti-migraine film

17. November 2009 06:48
IntelGenx Corp. is pleased to announce the results of a clinical pilot study that suggests IntelGenx has successfully developed a product that is bioequivalent to a leading branded anti-migraine therapy. The product (INT008) has been developed using IntelGenx's proprietary immediate release film "VersaFilm" drug delivery technology. VersaFilm provides a patent-protected method of formulating in a convenient and discrete dosage form. [More]

Posted in: Device / Technology News

Tags: , , ,

Positive results from Winston Laboratories' Civamide Patch trial

16. November 2009 08:41
Winston Laboratories, Inc., a wholly-owned subsidiary of Winston Pharmaceuticals, Inc. today announced positive top-line results from Study WL1001-04-03, a Phase II clinical trial evaluating the safety and efficacy of the company's patch formulation of Civamide, a novel TRPV-1 receptor modulator in the treatment of post-herpetic neuralgia (PHN). [More]

New market research report on osteoarthritis drugs

13. November 2009 04:09
Reportlinker.com announces that a new market research report is available in its catalogue: Musculo-Skeletal-Disorders Osteoarthritis [More]

Posted in: Pharmaceutical News

Tags:

Galapagos third quarter 2009 financial results in line with management expectations

13. November 2009 04:02
Galapagos NV announces today that third quarter 2009 operational and financial results were in line with management expectations. These results encourage the Company to retain full year guidance of EUR 100 million revenues, a growth of 30% compared to 2008. Galapagos' service division BioFocus will significantly increase its cash contribution to the Group result for the full year 2009. [More]

Posted in: Business / Finance

Tags: , , , , , , ,

Abbott signs agreement to acquire global rights to PanGenetics BV's PG110

13. November 2009 03:12
Abbott announced today a definitive agreement to acquire the global rights to PanGenetics BV's PG110 fully humanized antibody to Nerve Growth Factor (NGF), expanding the company's pain care portfolio and leveraging its expertise in biologics. PG110 is a novel biologic in Phase I clinical trial development that targets NGF for the treatment of chronic pain. [More]

Abbott to acquire the global rights to PanGenetics' new therapeutic for treatment of chronic pain

13. November 2009 02:02
PanGenetics, an antibody development company which is developing PG110, a humanized antibody to Nerve Growth Factor (NGF), today announced it has entered into an agreement with Abbott under which Abbott will acquire the global rights to this novel biologic. PG110 is currently in a Phase 1 clinical trial in patients with osteoarthritis and represents a promising new therapeutic for the treatment of chronic pain. [More]

NicOx reports top-line results from first-in-man study of its NO-donating HMG-CoA Reductase Inhibitor

13. November 2009 01:45
NicOx S.A. today announced that a phase 1b, first-in-man study for NCX 6560, versus placebo and Lipitor® (atorvastatin), has met its primary and secondary objectives. The top-line results demonstrated very good safety and tolerability for all the tested doses of NCX 6560, as well as the expected cholesterol lowering profile. [More]

Endo Pharmaceuticals reaches patent litigation settlement with LecTec

11. November 2009 23:48
Endo Pharmaceuticals announced today that it has reached a settlement with LecTec Corporation on outstanding patent litigation related to LecTec's U.S. Patent Nos. 5,536,263 and 5,741,510. [More]

Research and Markets' Competitive Intelligence Report on TGF-R agonists and antagonists

11. November 2009 07:53
Research and Markets has announced the addition of the "Competitor Analysis: TGF-R Agonists and Antagonists" report to their offering. [More]

GeneNews discloses financial results for third-quarter 2009

11. November 2009 07:34
GeneNews Limited, a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today reported operational and financial results for the third quarter-ended September 30, 2009. [More]
News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.